Drugs / ACE-86225106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06380660 | Mar 2024 → Dec 2028 expected | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast cancer, ovarian carcinoma +1 | Acerand Therapeutics (Shanghai) Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-17 | Acerand Therapeutics (Shanghai) Limited | Results Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors acerand.com ↗
ACE-106 showed encouraging and durable antitumor activity across tumor types. |
| 2025-05-30 | Acerand Therapeutics (Shanghai) Limited | Results Acerand Therapeutics Announces Preliminary Clinical Data of a Novel, Selective PARP1 Inhibitor ACE-86225106 to Be Presented at the 2025 ASCO Meeting acerand.com ↗
The findings, derived from the ongoing dose escalation and backfill cohorts of the Phase 1/2 clinical trial ACE-106-001 (NCT06380660) show preliminary evidence of good tolerability and encouraging efficacy in patients with heavily pre-treated advanced solid tumors. |
| 2023-11-03 | Acerand Therapeutics (Shanghai) Limited | Regulatory Acerand Therapeutics announced the approval of their next generation PARP1 selective inhibitor ACE-86225106 by CDE for clinic investigations acerand.com ↗
Acerand Therapeutics announced the approval of their next generation PARP1 selective inhibitor, ACE-86225106, for a first-in-human, open-label, multi-center Phase I/II study by the Center for Drug Evaluation of China National Medical Products Administration. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-17 | Acerand Therapeutics (Shanghai) Limited | Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors acerand.com ↗ |
| 2025-05-30 | Acerand Therapeutics (Shanghai) Limited | Acerand Therapeutics Announces Preliminary Clinical Data of a Novel, Selective PARP1 Inhibitor ACE-86225106 to Be Presented at the 2025 ASCO Meeting acerand.com ↗ |
| 2023-11-03 | Acerand Therapeutics (Shanghai) Limited | Acerand Therapeutics announced the approval of their next generation PARP1 selective inhibitor ACE-86225106 by CDE for clinic investigations acerand.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACE-86225106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06380660 ↗ |
| Action | Inhibit | “poly-ADP ribose polymerase (PARP) inhibitor” NCT06380660 ↗ |
| Route | Oral | “ACE-86225106 administered orally” NCT06380660 ↗ |